Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818702 | 0.89 | PPARG (0.47) | PPARAPPARGCYP2D6ACHECNR1 | |
| SCHEMBL2208586 | 0.89 | PPARG (0.47) | PPARAPPARGCYP2D6ACHECNR1 | |
| SCHEMBL13881800 | 0.86 | PPARG (0.45) | PPARAPPARGCYP2D6ACHECNR1 | |
| SCHEMBL24934293 | 0.86 | PPARA (0.57) | PPARAPPARGCYP2D6ACHEMTNR1A | |
| SCHEMBL29818840 | 0.85 | CYP2D6 (0.56) | CYP2D6ACHEKCNH2 | |
| SCHEMBL29818817 | 0.85 | CNR1 (0.52) | PPARAPPARGCYP2D6ACHECNR1 | |
| SCHEMBL2208515 | 0.85 | CNR1 (0.52) | PPARAPPARGCYP2D6ACHECNR1 | |
| SCHEMBL2207909 | 0.85 | CYP2D6 (0.56) | CYP2D6ACHEKCNH2 | |
| SCHEMBL4572152 | 0.84 | PPARA (0.59) | PPARAPPARGCYP2D6 | |
| SCHEMBL19291600 | 0.81 | CYP2D6 (0.55) | PPARAPPARGCYP2D6CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-9079825-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8993807-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8981153-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885CYP2D6 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.